Caris Assure™ detected clonal hematopoiesis (CH) mutations in ~40% of cases and demonstrated that CH identification and correction is vital for accurate therapy selection for cancer patients IRVING, Texas, Nov. 25, 2024 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading...
Caris Life Sciences Showcases Data Demonstrating the Clinical Value of Clonal Hematopoiesis Identification and Subtraction in Liquid Biopsy to Improve the Accuracy of Treatment Recommendations
Seaking AlphaSeeking Alpha / Seaking Alpha 6 hours ago 1 Views
Comments